Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?

Expert Review of Respiratory Medicine

Volumn 7, Issue 2 SUPPL., 2013, Pages 17-24

  Baloira, Adolfo ^a  

^a Department of Pulmonology   (Spain)

Author keywords

anticholinergic; bronchodilator; chronic obstructive pulmonary disease; combination; mimetic

Indexed keywords

ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG SELECTIVITY; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLAUCOMA; HUMAN; HYPOKALEMIA; LUNG FUNCTION; META ANALYSIS (TOPIC); PROGNOSIS; QT PROLONGATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SLEEP QUALITY; SPIROMETRY; TACHYCARDIA; TREATMENT DURATION; TREMOR; URINE RETENTION; XEROSTOMIA;

EID: 84875826056     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.13.18     Document Type: Article

References (33)

1. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of futicasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320, 1297-1303 (2000). (Pubitemid 30245717)
2. Calverley PM, Anderson JA, Celli B et al.; TORCH investigators. Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007). (Pubitemid 46294610)
3. Vestbo J, Edwards LD, Scanlon PD et al. ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 365, 1184-1192 (2011).
4. Hanania NA, Sharafkhaneh A, Celli B et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir. Res. 12, 6 (2011).
5. Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest 126, S125-S137 (2004).
6. Albert P, Agusti A, Edwards L et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 67(8), 701-708 (2012).
7. Soler-Cataluña JJ, Cosío B, Izquierdo JL et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch. Bronconeumol. 48(9), 331-337 (2012).
8. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 96, 984-987 (1989). (Pubitemid 19266543)
9. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analyses. JAMA 300, 1439-1450 (2008).
10. Hilleman DE, Malesker MA, Morrow LE, Schuller D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 253-263 (2009).
11. Westwood M, Boubeau J, Jones PW, Cerulli A, Capkun-Nigli G, Worthy G. Relationship between FEV#inf#1#/inf# change and patient-reported outcomes in randomized trials of inhaled bronchodilators for stable COPD: a systematic review. Respir. Res. 12, 40 (2011).
12. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 112, 336-340 (2011).
13. Dahl R, Greefhorst LA, Nowak D et al. Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, 778-784 (2001). (Pubitemid 32881913)
14. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217-224 (2002). (Pubitemid 34162820)
15. Jones PW, Mahler DA, Gale R, Owen R, Hramer B. Profling the effects of indacaterol on dyspnea and health status in patients with COPD. Respir. Med. 105, 892-899 (2011).
16. Donohue JF, Fogarty C, Lötvall J et al. INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease. Indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 182, 155-162 (2010).
17. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone. Chest 105, 1411-1419 (1994).
18. D'Urzo AD, De Salvo MC, Ramirez-Rivera A et al. FOR-INT-03 Study Group. In patients with COPD treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. A 3-week, randomized, double blind, whitin-patient, multicenter study. Chest 119, 1347-1356 (2001). (Pubitemid 32686014)
19. van Noord JA, de Munck DR, Banje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 15, 878-885 (2000). (Pubitemid 30321844)
20. Vincken W, van Noord JA, Greefhorst AP et al. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 years treatment with tiotropium. Eur. Respir. J. 19, 209-216 (2002). (Pubitemid 34162819)
21. Dahl R, Chung KF, Buhl R et al. INVOLVE (Indacaterol: Value in COPD: Longer Term Validation of Effcacy and Safety) Study Investigators. Effcacy of a new once-daily long-acting inhaler b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65, 473-479 (2010).
22. Kornmann O, Dahl R, Centanni S et al. INLIGHT-2 (Indacaterol Effcacy Evaluation Using 150-μ g Doses with COPD Patients) Study Investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo controlled study. Eur. Respir. J. 37, 273-279 (2011).
23. Baloira Villar A, Vilariño Pombo C. Bronchodilator effcacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch. Bronconeumol. 41, 130-134 (2005). (Pubitemid 40469297)
24. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of 'triple' therapy with salmeterol/futicasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63, 592-598 (2008). (Pubitemid 351969251)
25. van Noord JA, Aumann JL, Janssens E et al. Combining tiotropium ans salmeterol in COPD: effects on airfow obstruction and symptoms. Respir. Med. 104, 995-1004 (2010).
26. Cazzola M, Andò F, Santus P et al. A pilot study to assess the effects of combining futicasone/salmeterol and tiotropium on the airway obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 20, 556-561 (2007). (Pubitemid 47077647)
27. Aaron SD, Vandemheen KL, Fergusson D et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or futicasone salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146, 545-555 (2007). (Pubitemid 351650535)
28. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26, 214-222 (2005). (Pubitemid 41079064)
29. Vogelmeier C, Kardos P, Haari S, Gans SL, Stenglein S, Thirlvell J. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir. Med. 102, 1511-1520 (2008).
30. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus futicasone in moderate COPD. Chest 134, 255-262 (2008).
31. Welte T, Miravitlles M, Hernandez P et al. Effcacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180, 741-750 (2009).
32. Mahler DA, D'Urzo A, Bateman ED et al.; the INTRUST-1 and INTRUST-2 Study Investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilatation compared with tiotropium alone: a randomized, double blind comparison. Thorax 67(9), 781-788 (2012).
33. van Noord JA, Buhl R, Laforce C et al. QAV 149 demonstrates superior bronchodilatation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65, 1086-1091 (2010).